Opposite functions of HIF-α isoforms in VEGF induction by TGF-β1 under non-hypoxic conditions

[1]  Marta Piqueras,et al.  HIF-1α and HIF-2α Are Differentially Regulated In vivo in Neuroblastoma: High HIF-1α Correlates Negatively to Advanced Clinical Stage and Tumor Vascularization , 2009, Clinical Cancer Research.

[2]  E. Jones,et al.  Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model. , 2009, Cancer research.

[3]  M. Stearns,et al.  Role of the VEGFR3/VEGFD receptor axis in TGFβ1 activation of primary prostate cell lines , 2009, The Prostate.

[4]  S. Chi,et al.  NF-kappaB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signaling, to promote gastric tumorigenesis. , 2008, Gastroenterology.

[5]  Linda Holmquist Mengelbier,et al.  Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. , 2008, Cancer research.

[6]  D. Gisselsson,et al.  High levels of HIF‐2α highlight an immature neural crest‐like neuroblastoma cell cohort located in a perivascular niche , 2007, The Journal of pathology.

[7]  Zhongyun Dong,et al.  Smad3 Is Overexpressed in Advanced Human Prostate Cancer and Necessary for Progressive Growth of Prostate Cancer Cells in Nude Mice , 2007, Clinical Cancer Research.

[8]  D. Benjamin,et al.  mRNA stability and cancer: an emerging link? , 2007, Expert opinion on biological therapy.

[9]  L. Poellinger,et al.  Hypoxia Inducible Factor-2α in Cancer , 2007, Cell cycle.

[10]  K. Ha,et al.  Mechanisms underlying TGF‐β1‐induced expression of VEGF and Flk‐1 in mouse macrophages and their implications for angiogenesis , 2007, Journal of leukocyte biology.

[11]  Å. Borg,et al.  Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. , 2006, Cancer cell.

[12]  F. Rojo,et al.  Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. , 2006, Histology and histopathology.

[13]  Patrick H. Maxwell,et al.  Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma , 2005, Molecular and Cellular Biology.

[14]  Robyn M. B. Loureiro,et al.  Transcriptional regulation of vascular endothelial growth factor in cancer. , 2005, Cytokine & growth factor reviews.

[15]  M. Tachibana,et al.  Prognostic Impact of Hypoxia-Inducible Factors 1α and 2α in Colorectal Cancer Patients , 2004, Clinical Cancer Research.

[16]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[17]  J. Brown,et al.  Exploiting tumour hypoxia in cancer treatment , 2004, Nature Reviews Cancer.

[18]  M. Matthay,et al.  Prolonged Hypoxia Differentially Regulates Hypoxia-inducible Factor (HIF)-1α and HIF-2α Expression in Lung Epithelial Cells , 2004, Journal of Biological Chemistry.

[19]  A. Harris,et al.  Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. , 2003, Melanoma research.

[20]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[21]  Y. Nagamine,et al.  Stabilization of Urokinase and Urokinase Receptor mRNAs by HuR Is Linked to Its Cytoplasmic Accumulation Induced by Activated Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 , 2003, Molecular and Cellular Biology.

[22]  A. Harris,et al.  839 Hypoxia-inducible factors 1a and 2a in skin malignant melanomas , 2003 .

[23]  G. Semenza,et al.  Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. , 2003, Cancer research.

[24]  P. Neuhaus,et al.  Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. , 2003, Cancer research.

[25]  Mirna Lechpammer,et al.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.

[26]  Richard D Klausner,et al.  The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. , 2002, Cancer cell.

[27]  D. Horsfall,et al.  A potential autocrine role for vascular endothelial growth factor in prostate cancer. , 2002, Cancer research.

[28]  D. A. Dixon,et al.  Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. , 2001, The Journal of clinical investigation.

[29]  Liliana Attisano,et al.  Synergistic Cooperation between Hypoxia and Transforming Growth Factor-β Pathways on Human Vascular Endothelial Growth Factor Gene Expression* , 2001, The Journal of Biological Chemistry.

[30]  Myriam Gorospe,et al.  Loss of HuR Is Linked to Reduced Expression of Proliferative Genes during Replicative Senescence , 2001, Molecular and Cellular Biology.

[31]  G. Semenza,et al.  HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression , 2001, Molecular and Cellular Biology.

[32]  L. Nabors,et al.  HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3' untranslated regions of cytokine and angiogenic factor mRNAs. , 2001, Cancer research.

[33]  A. Harris,et al.  Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. , 2000, Cancer research.

[34]  Myriam Gorospe,et al.  HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation , 2000, The EMBO journal.

[35]  G. Semenza,et al.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.

[36]  J. Rhim,et al.  Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  J. Steitz,et al.  HNS, a nuclear-cytoplasmic shuttling sequence in HuR. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  G. Semenza.  Hypoxia-inducible factor 1: master regulator of O2 homeostasis. , 1998, Current opinion in genetics & development.

[39]  Kohei Miyazono,et al.  TGF-β signalling from cell membrane to nucleus through SMAD proteins , 1997, Nature.

[40]  K. Miyazono,et al.  Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  P. Scardino,et al.  Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  M. Steiner.  Transforming growth factor-β and prostate cancer , 1995, World Journal of Urology.

[43]  D. Mukhopadhyay,et al.  Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation , 1995, Nature.

[44]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Dufour,et al.  Cell lines , 2012, Spermatogenesis.

[46]  Ma Hongbao,et al.  Hypoxia inducible factor (HIF) , 2010 .

[47]  M. Charbonneau,et al.  Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. , 2006, The Journal of biological chemistry.

[48]  N. Kyprianou,et al.  Transforming growth factor beta and prostate cancer. , 2005, Cancer treatment and research.

[49]  Mary E. Choi,et al.  Transforming growth factor-beta1 stimulates vascular endothelial growth factor 164 via mitogen-activated protein kinase kinase 3-p38alpha and p38delta mitogen-activated protein kinase-dependent pathway in murine mesangial cells. , 2004, The Journal of biological chemistry.

[50]  G. Semenza,et al.  Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. , 2004, Cancer detection and prevention.

[51]  M. Tachibana,et al.  Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  M. Matthay,et al.  Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural antisense HIF-1alpha. , 2004, The Journal of biological chemistry.

[53]  S. Chi,et al.  Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways1 , 2004 .

[54]  R. Derynck,et al.  Smad-dependent and Smad-independent pathways in TGF-beta family signalling. , 2003, Nature.

[55]  J. Massagué,et al.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus. , 2003, Cell.

[56]  菅野 康.  Distortion of autocrine transforming growth factor β signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells , 2003 .

[57]  H. Ryan,et al.  HIF-1 alpha is required for solid tumor formation and embryonic vascularization. , 1998, The EMBO journal.

[58]  J. Trapman,et al.  The androgen receptor in prostate cancer. , 1996, Pathology, research and practice.

[59]  P. Scardino,et al.  Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. , 1993, Human pathology.

[60]  J. Massagué,et al.  The transforming growth factor-beta family. , 1990, Annual review of cell biology.